Cost-effectiveness of a novel e-health depression service

Telemedicine and e-Health

Volumn 19, Issue 2, 2013, Pages 110-116

  Naveršnik, Klemen ^a   Mrhar, Aleš ^b  

^a Lek dd   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Business administration economics; E health; Policy; Telepsychiatry

Indexed keywords

COST EFFECTIVENESS; COSTS; HEALTH; LINEAR TRANSFORMATIONS; MATHEMATICAL TRANSFORMATIONS; PIECEWISE LINEAR TECHNIQUES; PUBLIC POLICY; STOCHASTIC MODELS; STOCHASTIC SYSTEMS; UNCERTAINTY ANALYSIS;

BECK DEPRESSION INVENTORIES; BUSINESS ADMINISTRATION/ECONOMICS; E HEALTH; HEALTH ECONOMIC EVALUATIONS; PIECEWISE-LINEAR TRANSFORMATION; QUALITY ADJUSTED LIFE YEARS; TELEPSYCHIATRY; VALUE OF INFORMATION;

COST BENEFIT ANALYSIS;

COST BENEFIT ANALYSIS; DEPRESSION; ECONOMICS; FEMALE; HUMAN; INTERVENTION STUDY; MALE; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; SEVERITY OF ILLNESS INDEX; TELEMEDICINE; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DEPRESSION; FEMALE; HUMANS; INTERVENTION STUDIES; MALE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; TELEMEDICINE; TREATMENT OUTCOME;

EID: 84891643082     PISSN: 15305627     EISSN: 15563669     Source Type: Journal    
DOI: 10.1089/tmj.2012.0081     Document Type: Article

References (37)

1. National Institute for Health and Clinical Excellence. Depression: Treatment and management of depression in adults. Clinical guideline 90. London: National Institute for Health and Clinical Excellence, 2009.
2. Robinson WD, Geske JA, Prest LA, et al. Depression treatment in primary care. J Am Board Fam Pract 2005;18: 79-86. (Pubitemid 41664011)
3. Conner TM, Crimson ML, Still DJ. A critical review of selected pharmacoeconomic analyses of antidepressant therapy. Ann Pharmacother 1999;33: 364-372. (Pubitemid 29157749)
4. Rost K. Disability from depression: The public health challenge to primary care. Nord J Psychiatry 2009;63: 17-21.
5. Meglic M, Brodnik A. Electronic environments for integrated care management: case of depression. In: Mohammed S, Fiaidhi J, eds. Ubiquitous health and medical informatics: The Ubiquity 2.0 trend and beyond. Hershey, PA: IGI Global, 2010.
6. Meglic M, Furlan M, Kuzmanic M, et al. Feasibility of an ehealth service to support collaborative depression care: Results of a pilot study. J Med Internet Res 2010;12:e63.
7. Vannoy SD, Arean P, Unützer J. Advantages of using estimated depression-free days for evaluating treatment efficacy. Psychiatr Serv 2010;61: 160-163.
8. Pyne JM, Tripathi S, Williams DK, et al. Depression-free day to utility-weighted score: Is it valid? Med Care 2007;45: 357-362.
9. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence, 2008.
10. Parker M, Haycox A, Graves J. Estimating the relationship between preferencebased generic utility instruments and disease-specific quality-of life measures in severe chronic constipation: Challenges in practice. Pharmacoeconomics 2011;29: 719-730.
11. Lave JR, Frank RG, Schulberg HC, et al. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998;55: 645-651. (Pubitemid 28340354)
12. Rost K, Pyne JM, Dickinson LM, et al. Cost-effectiveness of enhancing primary care depression management on an ongoing basis. Ann Fam Med 2005;3: 7-14. (Pubitemid 40203942)
13. Katon W, Unutzer J, Fan MY, et al. Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care 2006;29: 265-270. (Pubitemid 44106502)
14. Jonkers CC, Lamers F, Evers SM, et al. Cost-utility estimates in depression: Does the valuation method matter? J Ment Health Policy Econ 2010;13: 189-197.
15. Brazier J. Is the EQ-5D fit for purpose in mental health? Br J Psychiatry 2010;197: 348-349.
16. Valenstein M, Vijan S, Zeber JE, et al. The cost-utility of screening for depression in primary care. Ann Intern Med 2001;134: 345-360. (Pubitemid 32179474)
17. Revicki DA, Wood M. Patient-assigned health state utilities for depressionrelated outcomes: Differences by depression severity and antidepressant medications. J Affect Disord 1998;48: 25-36. (Pubitemid 28078968)
18. Freed MC, Rohan KJ, Yates BT. Estimating health utilities and quality adjusted life years in seasonal affective disorder research. J Affect Disord 2007;100: 83-89. (Pubitemid 46818431)
19. Jones MT, Cockrum PC. A critical review of published economic modeling studies in depression. Pharmacoeconomics 2000;17: 555-583. (Pubitemid 30407881)
20. Berto P, D'Ilario D, Ruffo P, et al. Depression: Cost-of-illness studies in the international literature, a review. J Mental Health Policy Econ 2000;3;3-10.
21. Krol M, Papenburg J, Koopmanschap M, et al. Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics 2011;29: 601-619.
22. Tranmer JE, Guerriere DN, Ungar WJ, et al. Valuing patient and caregiver time: A review of the literature. Pharmacoeconomics 2005;23: 449-459. (Pubitemid 40994134)
23. Beck AT, Brown G, Steer RA. Beck Depression Inventory II manual. San Antonio, TX: The Psychological Corporation, 1996.
24. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making 1998;18: 95-109. (Pubitemid 28041646)
25. Kaltenthaler E, Brazier J, De Nigris E, et al. Computerised cognitive behaviour therapy for depression and anxiety update: A systematic review and economic evaluation. Health Technol Assess 2006;10: 1-186.
26. Naveršnik K, Rojnik K. Handling input correlations in pharmacoeconomic models. Value Health 2012;15: 540-549.
27. McCrone P, Knapp M, Proudfoot J, et al. Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: Randomised controlled trial. Br J Psychiatry 2004;185: 55-62. (Pubitemid 38951630)
28. Higgins JP, White IR, Wood AM. Imputation methods for missing outcome data in meta-analysis of clinical trials. Clin Trials 2008;5: 225-239.
29. Seggar LB, Lambert MJ, Hansen NB. Assessing clinical significance: Application to the Beck Depression Inventory. Behav Ther 2002;33: 253-269. (Pubitemid 36527804)
30. Marušič D, Kenda R, Novak M, et al. Postopek ocenjevanja in vključevanja novih ali spremenjenjih zdravstvenih programov in drugih novosti pri metodah dela v programe zdravstvene dejavnosti v Republiki Sloveniji. Ministrstvo za Zdravje, Ljubljana, Slovenia. Publication number 0130-57/2009-4. Available at www .mz.gov.si/fileadmin/mz.gov.si/pageuploads/ZS- IN-RSK/Postopek-uvodni- del.pdf (last accessed March 27, 2012).
31. Katon WJ, Schoenbaum M, Fan MY, et al. Cost-effectiveness of improving primary care treatment of late-life depression. Arch Gen Psychiatry 2005;62: 1313-1320. (Pubitemid 41746609)
32. Jain R, Grabner M, Onukwugha E. Sensitivity analysis in cost-effectiveness studies: From guidelines to practice. Pharmacoeconomics 2011;29: 297-314.
33. Haji Ali Afzali H, Karnon J, Gray J. A proposed model for economic evaluations of major depressive disorder. Eur J Health Econ 2011;13: 201-510.
34. Birch S, Gafni A. Information created to evade reality (ICER): Things we should not look to for answers. Pharmacoeconomics 2006;24: 1121-1131. (Pubitemid 44683368)
35. Claxton K. OFT, VBP: QED? Health Econ 2007;16: 545-558.
36. Freemantle N, Maynard A. Something rotten in the state of clinical and economic evaluations? Health Econ 1994;3: 63-67.
37. Kruger J, Dunning D. Unskilled and unaware of it: How difficulties in recognizing one's own incompetence lead to inflated self-assessments. J Pers Soc Psychol 1999;77: 1121-1134.